Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Mirum Awards $770K in Stock Options and RSUs at $53 Per Share to Key New Hires - Stock Titan

Mirum Awards $770K in Stock Options and RSUs at $53 Per Share to Key New Hires  Stock Titan

Mirum Awards $770K in Stock Options and RSUs at $53 Per Share to Key New Hires - Stock Titan

Click here to get full coverage on Case Report: Mycoplasma pneumoniae-Induced Rash and Mucositis (MIRM) in a Child - Frontiers

Case Report: Mycoplasma pneumoniae-Induced Rash and Mucositis (MIRM) in a Child  Frontiers

Case Report: Mycoplasma pneumoniae-Induced Rash and Mucositis (MIRM) in a Child - Frontiers

Click here to get full coverage on Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? - Yahoo Finance

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?  Yahoo Finance

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities - Seeking Alpha

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities  Seeking Alpha

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities - Seeking Alpha

Click here to get full coverage on Mirum Pharmaceuticals Insiders Sold US$2.2m Of Shares Suggesting Hesitancy - simplywall.st

Mirum Pharmaceuticals Insiders Sold US$2.2m Of Shares Suggesting Hesitancy  simplywall.st

Mirum Pharmaceuticals Insiders Sold US$2.2m Of Shares Suggesting Hesitancy - simplywall.st

Click here to get full coverage on When (MIRM) Moves Investors should Listen - news.stocktradersdaily.com

When (MIRM) Moves Investors should Listen  news.stocktradersdaily.com

When (MIRM) Moves Investors should Listen - news.stocktradersdaily.com

Click here to get full coverage on Interesting MIRM Put And Call Options For August 15th - Nasdaq

Interesting MIRM Put And Call Options For August 15th  Nasdaq

Interesting MIRM Put And Call Options For August 15th - Nasdaq

Click here to get full coverage on Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up - Investor's Business Daily

Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up  Investor's Business Daily

Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up - Investor's Business Daily

Click here to get full coverage on Mirum Pharmaceuticals, Inc.(NasdaqGM: MIRM) dropped from Russell 3000E Index - MarketScreener

Mirum Pharmaceuticals, Inc.(NasdaqGM: MIRM) dropped from Russell 3000E Index  MarketScreener

Mirum Pharmaceuticals, Inc.(NasdaqGM: MIRM) dropped from Russell 3000E Index - MarketScreener

Click here to get full coverage on Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey

Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts  Insider Monkey

Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey

Click here to get full coverage on Together, We Innovate: Driving Regenerative Medicine Through Collaboration - BioProcess International

Together, We Innovate: Driving Regenerative Medicine Through Collaboration  BioProcess International

Together, We Innovate: Driving Regenerative Medicine Through Collaboration - BioProcess International

Click here to get full coverage on Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates  Yahoo Finance

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic? - simplywall.st

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic?  simplywall.st

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic? - simplywall.st

Click here to get full coverage on FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI - Stock Titan

FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI  Stock Titan

FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI - Stock Titan

Click here to get full coverage on Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM) - Seeking Alpha

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM)  Seeking Alpha

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) (MIRM) - Seeking Alpha

Click here to get full coverage on (MIRM) Investment Report - news.stocktradersdaily.com

(MIRM) Investment Report  news.stocktradersdaily.com

(MIRM) Investment Report - news.stocktradersdaily.com

Click here to get full coverage on Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (MIRM) - Seeking Alpha

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (MIRM)  Seeking Alpha

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (MIRM) - Seeking Alpha

Click here to get full coverage on First Week of MIRM March 21st Options Trading - Nasdaq

First Week of MIRM March 21st Options Trading  Nasdaq

First Week of MIRM March 21st Options Trading - Nasdaq

Click here to get full coverage on Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (NASDAQ:MIRM) - Seeking Alpha

Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (NASDAQ:MIRM)  Seeking Alpha

Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (NASDAQ:MIRM) - Seeking Alpha

Click here to get full coverage on Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - simplywall.st

Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations  simplywall.st

Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - simplywall.st

Click here to get full coverage on Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 - Business Wire

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025  Business Wire

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 - Business Wire

Click here to get full coverage on Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt? - simplywall.st

Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?  simplywall.st

Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt? - simplywall.st

Click here to get full coverage on Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - Yahoo Finance

Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised  Yahoo Finance

Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - Yahoo Finance

Click here to get full coverage on Figure 1. 11-year-old boy with conjunctivitis due to MIRM. MIRM,... - researchgate.net

Figure 1. 11-year-old boy with conjunctivitis due to MIRM. MIRM,...  researchgate.net

Figure 1. 11-year-old boy with conjunctivitis due to MIRM. MIRM,... - researchgate.net

Click here to get full coverage on MIRM: A New Disease Entity Comes Into Focus - American Academy of Ophthalmology

MIRM: A New Disease Entity Comes Into Focus  American Academy of Ophthalmology

MIRM: A New Disease Entity Comes Into Focus - American Academy of Ophthalmology

Click here to get full coverage on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Is Breakeven Near? - 富途牛牛

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Is Breakeven Near?  富途牛牛

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Is Breakeven Near? - 富途牛牛

Click here to get full coverage on JMP maintains $74 target on Mirum Pharmaceuticals stock - Investing.com

JMP maintains $74 target on Mirum Pharmaceuticals stock  Investing.com

JMP maintains $74 target on Mirum Pharmaceuticals stock - Investing.com

Click here to get full coverage on Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations  Yahoo Finance

Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Click here to get full coverage on Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - Business Wire

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update  Business Wire

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on Mirum Pharmaceuticals president sells $126,680 in stock - Investing.com

Mirum Pharmaceuticals president sells $126,680 in stock  Investing.com

Mirum Pharmaceuticals president sells $126,680 in stock - Investing.com

Click here to get full coverage on Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer - Business Wire

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer  Business Wire

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer - Business Wire

Click here to get full coverage on Careers in Stem Cell & Regenerative Biology: Opportunities in Research, Industry & Clinics – MIRM - BioTecNika

Careers in Stem Cell & Regenerative Biology: Opportunities in Research, Industry & Clinics – MIRM  BioTecNika

Careers in Stem Cell & Regenerative Biology: Opportunities in Research, Industry & Clinics – MIRM - BioTecNika

Click here to get full coverage on Biotecnika Hosts Insightful Webinar on Exploring Careers in Stem Cells with Dr. Sveta Chakrabarti, MIRM Bengaluru - BioTecNika

Biotecnika Hosts Insightful Webinar on Exploring Careers in Stem Cells with Dr. Sveta Chakrabarti, MIRM Bengaluru  BioTecNika

Biotecnika Hosts Insightful Webinar on Exploring Careers in Stem Cells with Dr. Sveta Chakrabarti, MIRM Bengaluru - BioTecNika

Click here to get full coverage on Painful mucositis in an 8-year-old boy - Healio

Painful mucositis in an 8-year-old boy  Healio

Painful mucositis in an 8-year-old boy - Healio

Click here to get full coverage on Biotecnika Successfully Hosted a Power-Packed Webinar with MIRM’s Dr. Anujit Kumar on Top Stem Cell Research Institutes - BioTecNika

Biotecnika Successfully Hosted a Power-Packed Webinar with MIRM’s Dr. Anujit Kumar on Top Stem Cell Research Institutes  BioTecNika

Biotecnika Successfully Hosted a Power-Packed Webinar with MIRM’s Dr. Anujit Kumar on Top Stem Cell Research Institutes - BioTecNika

Click here to get full coverage on MIRM Admissions 2025: Apply For MSc in Stem Cell Technology and Regenerative Biology at Manipal Institute of Regenerative Medicine - BioTecNika

MIRM Admissions 2025: Apply For MSc in Stem Cell Technology and Regenerative Biology at Manipal Institute of Regenerative Medicine  BioTecNika

MIRM Admissions 2025: Apply For MSc in Stem Cell Technology and Regenerative Biology at Manipal Institute of Regenerative Medicine - BioTecNika

Click here to get full coverage on Mycoplasma pneumoniae‐Induced Rash and Mucositis (MIRM) Mimicking Behçet’s Disease and Paraneoplastic Pemphigus (PNP) - Wiley Online Library

Mycoplasma pneumoniae‐Induced Rash and Mucositis (MIRM) Mimicking Behçet’s Disease and Paraneoplastic Pemphigus (PNP)  Wiley Online Library

Mycoplasma pneumoniae‐Induced Rash and Mucositis (MIRM) Mimicking Behçet’s Disease and Paraneoplastic Pemphigus (PNP) - Wiley Online Library

Click here to get full coverage on Case Report and Literature Review: Clinical Characteristics of 10 Children With Mycoplasma pneumoniae-Induced Rash and Mucositis - Frontiers

Case Report and Literature Review: Clinical Characteristics of 10 Children With Mycoplasma pneumoniae-Induced Rash and Mucositis  Frontiers

Case Report and Literature Review: Clinical Characteristics of 10 Children With Mycoplasma pneumoniae-Induced Rash and Mucositis - Frontiers

Click here to get full coverage on Mirum Pharmaceuticals: Advancing On Several Key Fronts (NASDAQ:MIRM) - Seeking Alpha

Mirum Pharmaceuticals: Advancing On Several Key Fronts (NASDAQ:MIRM)  Seeking Alpha

Mirum Pharmaceuticals: Advancing On Several Key Fronts (NASDAQ:MIRM) - Seeking Alpha

Click here to get full coverage on Raymond James Maintains Mirum Pharmaceuticals (MIRM) Strong Buy Recommendation - Nasdaq

Raymond James Maintains Mirum Pharmaceuticals (MIRM) Strong Buy Recommendation  Nasdaq

Raymond James Maintains Mirum Pharmaceuticals (MIRM) Strong Buy Recommendation - Nasdaq

Click here to get full coverage on Army Kills APKWS Rockets & Mystery Missile, MIRM - Breaking Defense

Army Kills APKWS Rockets & Mystery Missile, MIRM  Breaking Defense

Army Kills APKWS Rockets & Mystery Missile, MIRM - Breaking Defense

Click here to get full coverage on Mirum Pharma gains amid report of approach from Swedish Orphan Biovitrum - MSN

Mirum Pharma gains amid report of approach from Swedish Orphan Biovitrum  MSN

Mirum Pharma gains amid report of approach from Swedish Orphan Biovitrum - MSN

Click here to get full coverage on Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Business Wire

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024  Business Wire

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Business Wire

Click here to get full coverage on PhD Positions Open in Stem Cell Cytometry and Imaging Lab, Manipal Institute of Regenerative Medicine (MIRM), Bengaluru - BioTecNika

PhD Positions Open in Stem Cell Cytometry and Imaging Lab, Manipal Institute of Regenerative Medicine (MIRM), Bengaluru  BioTecNika

PhD Positions Open in Stem Cell Cytometry and Imaging Lab, Manipal Institute of Regenerative Medicine (MIRM), Bengaluru - BioTecNika

Click here to get full coverage on UWL student Mirm Hurula protests through art - The Racquet Press

UWL student Mirm Hurula protests through art  The Racquet Press

UWL student Mirm Hurula protests through art - The Racquet Press

Click here to get full coverage on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2022 Earnings Call Transcript - Yahoo Finance

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2022 Earnings Call Transcript  Yahoo Finance

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2022 Earnings Call Transcript - Yahoo Finance

Click here to get full coverage on Biotech Stock Explodes On Drug Trial News As Sales Continue To Double - Investor's Business Daily

Biotech Stock Explodes On Drug Trial News As Sales Continue To Double  Investor's Business Daily

Biotech Stock Explodes On Drug Trial News As Sales Continue To Double - Investor's Business Daily

Click here to get full coverage on Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Nasdaq

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  Nasdaq

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Nasdaq

Click here to get full coverage on MIRM - Mirum Pharmaceuticals Latest Stock News & Market Updates - Stock Titan

MIRM - Mirum Pharmaceuticals Latest Stock News & Market Updates  Stock Titan

MIRM - Mirum Pharmaceuticals Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates  Yahoo Finance

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Eliminating Preparation of Multisample External Calibration Curves and Dilution of Study Samples Using the Multiple Isotopologue Reaction Monitoring (MIRM) Technique in Quantitative LC-MS/MS Bioanalysis - ACS Publications

Eliminating Preparation of Multisample External Calibration Curves and Dilution of Study Samples Using the Multiple Isotopologue Reaction Monitoring (MIRM) Technique in Quantitative LC-MS/MS Bioanalysis  ACS Publications

Eliminating Preparation of Multisample External Calibration Curves and Dilution of Study Samples Using the Multiple Isotopologue Reaction Monitoring (MIRM) Technique in Quantitative LC-MS/MS Bioanalysis - ACS Publications

Click here to get full coverage on Mirum Pharmaceuticals (MIRM) Earnings Date and Reports 2025 - MarketBeat

Mirum Pharmaceuticals (MIRM) Earnings Date and Reports 2025  MarketBeat

Mirum Pharmaceuticals (MIRM) Earnings Date and Reports 2025 - MarketBeat

Click here to get full coverage on Mycoplasma-Induced Rash and Mucositis: 2 Cases in Adults - Consultant360

Mycoplasma-Induced Rash and Mucositis: 2 Cases in Adults  Consultant360

Mycoplasma-Induced Rash and Mucositis: 2 Cases in Adults - Consultant360

Click here to get full coverage on Mycoplasma pneumoniae–Induced Rash and Mucositis: 2 Pediatric Cases - Consultant360

Mycoplasma pneumoniae–Induced Rash and Mucositis: 2 Pediatric Cases  Consultant360

Mycoplasma pneumoniae–Induced Rash and Mucositis: 2 Pediatric Cases - Consultant360

Click here to get full coverage on Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update - Stock Titan

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update  Stock Titan

Mirum Pharmaceuticals Inc (MIRM)

Price Chart

Key Statistics

Technicals

About MIRM

Latest News

Mirum Awards $770K in Stock Options and RSUs at $53 Per Share to Key New Hires - Stock Titan

Case Report: Mycoplasma pneumoniae-Induced Rash and Mucositis (MIRM) in a Child - Frontiers

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers